Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Biofrontera Inc.

#NowHiring: The #Biofrontera team is searching for a new Jr. Territory Manager in Chicago, IL! 

If you're ready to make a difference in #dermatology, visit ⤵️

#SalesPosition #ComeGrowWithUs

📢 We're hiring a Territory Manager in Chicago, IL! 

Ready to help the #Biofrontera team spread the word about our innovative dermatological treatments? Apply today ⤵️ 

#ComeGrowWithUs

Today we shared #Bioftonera's #Q3 financial results for 2023. To learn more, visit the link below: ⤵️

#BiofronteraNews #Dermatology

Meet #Biofrontera Quality Assurance Director, Darrell Lowman! Darrell has been instrumental in our success as a company and is a natural-born leader. We are lucky to have him!

To learn more about our team, visit: https://loom.ly/xeWeBoE

#GetToKnowUs #PDT #EmployeeSpotlight #Dermatology

Are you a #Dermatology NP or PA and looking to transition to industry? Are you located in the Northeast? Do you want to join a dynamic team and fuel your career growth? If so, please check out #Biofrontera's open position for a Medical Science Liaison. ⤵️

#ComeGrowWithUs #NowHiring

#Biofrontera was happy to support and take part in the YoungMD Connect Networking Event this weekend in Chicago, connecting with some of the rising stars of #dermatology!

Thank you to Sally Cioci Fischer and the Practical Dermatology team for organizing such a great event!

Mouna Mikati, Ph.D. Kristina Malkhasova, Pharm. D. 

#BiofronteraontheMove

Join the #Biofrontera team as a Senior Financial Analyst at our headquarters in Woburn, MA! 

Discover how you can help to make a difference in #dermatology. Apply now ⤵️

We had a great time at the Ohio Dermatological Annual Meeting this past weekend! It's always a pleasure running into Dr. Scott Drew and Delaney Drew.

Thank you to our own Amy Ward Cline for holding down the booth and sharing the latest about 

#Biofrontera! #BiofronteraOnTheMove #Dermatology

We have news! To learn more about the latest #Biofrontera updates, visit: https://loom.ly/ZfcmM4o

#BiofronteraNews #Dermatology

Happy Halloween from all of us at #Biofrontera! Our latest training class joined some of our HQ team for a spooktacular time at our annual Halloween celebration. 

We celebrated with a costume contest as well a painting contest and DIY cookie decorating!

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Apple Mobile Web Clips Icon

Global Site Tag

DoubleClick.Net

US Privacy User Signal Mechanism

DNSSEC

Microsoft Exchange Online

Director of Information Technology

Andrew Weinburger

Junior Product Manager

Anika Hergarten

Territory Sales Manager

Beth Hodgkiss

Territory Manager

Dina Rury

Deputy Project Manager

Janlyn Murphy

Senior Territory Manager

Jill Zaback

Regional Sales Manager

Kathryn Demko

Executive Territory Manager

Lisa Villegas

Sr. Territory Manager

Maurice Horgan

Hermann Lubbert

CEO and founder

Ludwig Lutter

Chief Financial Officer

Nordrhein-Westfalen Companies With More Than $1M in Revenue (Top 10K)

Health Care Public Companies With More Than 50 Employees

European Union (EU) Public Companies

European Union (EU) Public Companies With Less Than $500M in Revenue

Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin.

In February 2012 Biofrontera launched the prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through various local representatives. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012.

US FDA approval of Ameluz® and activating PDT-lamp BF-RhodoLED® for the treatment of actinic keratoses was granted in May 2016.

As a cosmeceutical product Biofrontera markets Belixos® creme for the regenerative care of reddened and inflamed skin. It is Biofrontera’s intention to develop a line of cosmeceutical products for damaged skin under the Belixos brand.


The Biofrontera Group consists of the parent company Biofrontera AG and five wholly owned direct subsidiaries - Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH, Biofrontera Neuroscience GmbH and Biofrontera Inc. Biofrontera Inc. has its registered office in Wakefield, MA, USA. All the other companies are based at Hemmelrather Weg 201 in 51377 Leverkusen, Germany.

The listed public limited company (AG in German) has a holding function in the group of companies and ensures the necessary financing for the Group. Biofrontera Bioscience GmbH undertakes the research and development tasks for the Group and is the holder of patents and the approval for Ameluz®. Based on a licence agreement with Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, which is also the holder of the approval for BF-RhodoLED®, is responsible for the manufacturing and also the further licensing and marketing of the Biofrontera Group’s approved products.

Biofrontera Development GmbH and Biofrontera Neuroscience GmbH were established as additional wholly owned subsidiaries of Biofrontera AG in December 2012. The purpose of both companies is to pursue the further development of pipeline products that are not part of Biofrontera's core business and therefore cannot be sufficiently financed within the framework of normal business development. The product BF-derm1, which is intended for the treatment of severe chronic urticaria, is the responsibility of Biofrontera Development GmbH, while the product BF-1, which is intended for the prophylactic treatment of migraines, is the responsibility of Biofrontera Neuroscience GmbH. By outsourcing the development projects, a structure has been created through which the financing of the further development of these two products can be separated from the normal Group financing.

Biofrontera Inc. was established in March 2015 and will be used to conduct business in the USA.

Post-IPO Equity - Biofrontera

Leverkusen

Nordrhein-Westfalen

Germany

Europe

Biofrontera

Biofrontera Inc reports results for the quarter ended in June - Earnings Summary

Earnings call: Biofrontera reports Q1 2024 financials amid recovery

Biofrontera Inc. Reports First Quarter 2024 Financial Res...

Novavax, MacroGenics, Biofrontera among healthcare movers

Biofrontera Inc. to Report First Quarter 2024 Financial R...

Biofrontera files to sell 11.31M shares for holders

Biofrontera Inc. Announces 2024 Annual Meeting of Stockho...

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2...

Biofrontera Inc reports results for the quarter ended in December - Earnings Summary

Biofrontera files to sell 9.31M shares of common stock for holders

India

Asia

United States

North America

Japan

HTML5

Google Analytics

Google Fonts

Apache Server

jQuery

F5 NGINX

Vimeo

GoDaddy Premium DNS

Adobe Fonts

Fonts.com

A global dermatology company that develops and markets dermatological products and medical solutions.

Galderma

A multinational pharmaceutical company specializing in dermatology and critical care.

LEO Pharma

A leading global healthcare supplier that develops, manufactures, and distributes over-the-counter and prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients.

Perrigo Company plc

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. The company's flagship drug, Ameluz®, is FDA-approved for the treatment of actinic keratoses (AK) when used in combination with photodynamic therapy (PDT) and Biofrontera’s BF-RhodoLED® lamp. Additionally, Biofrontera commercializes the drug Xepi® for the treatment of impetigo.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

news impact assignment basic	general	Feb 20, 2024 7:14 PM	63d6f38a
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 20, 2024 7:14 PM	1bd28f1e
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	9298ec99
crunchbase profile	general	Oct 30, 2024 5:24 AM	29f85436
li profile	general	Feb 20, 2024 7:14 PM	cbdc4cef
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	c2287a25
peers	general	Feb 20, 2024 7:14 PM	2ed59d59
news basic	general	Feb 20, 2024 7:14 PM	8491f6a2
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:BIOFRONTERA-US

Biofrontera Inc.

Last Close

0.76

22/11 21:00

Market Cap

4.99M

Beta: -

Volume Today

820.43K

Avg: -